|
KMID : 0043320180410070691
|
|
Archives of Pharmacal Research
2018 Volume.41 No. 7 p.691 ~ p.710
|
|
|
Synthetic cannabinoids are substrates and inhibitors of multiple drug-metabolizing enzymes
|
|
Kong Tae-Yeon
Kim Ju-Hyun
Kim Dong-Kyun
Lee Hye-Suk
|
|
|
Abstract
|
|
|
|
Synthetic cannabinoids, a new class of psychoactive substances, are potent agonists of cannabinoid receptors, which mimic the psychoactive effects of the principal psychoactive component of cannabis, ?9-tetrahydrocannabinol. Despite governmental scheduling as illicit drugs, new synthetic cannabinoids are being produced. The abuse of synthetic cannabinoids with several drugs containing different chemical groups has resulted in large numbers of poisonings. This has increased the urgency for forensic and public health laboratories to identify the metabolites of synthetic cannabinoids and apply this knowledge to the development of analytical methods and for toxicity prediction. It is necessary to determine whether synthetic cannabinoids are involved in drug-metabolizing enzyme-mediated drug?drug interactions. This review describes the metabolic pathways of 13 prevalent synthetic cannabinoids and various drug-metabolizing enzymes responsible for their metabolism, including cytochrome P450 (CYP), UDP-glucuronosyltransferases (UGTs), and carboxylesterases. The inhibitory effects of synthetic cannabinoids on CYP and UGT activities are also reviewed to predict the potential of synthetic cannabinoids for drug?drug interactions. The drug-metabolizing enzymes responsible for metabolism of synthetic cannabinoids should be characterized and the effects of synthetic cannabinoids on CYP and UGT activities should be determined to predict the pharmacokinetics of synthetic cannabinoids and synthetic cannabinoid-induced drug?drug interactions in the clinic.
|
|
|
KEYWORD
|
|
|
Cannabinoids, Metabolism, Cytochrome P450, UDP-glucuronosyltransferases, Drug interaction
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|